Navigation Links
Phase 1 ALS trial is first to test antisense treatment of neurodegenerative disease
Date:4/3/2013

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis (ALS) blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease may be a first step towards a new era in the treatment of such disorders. Investigators from Massachusetts General Hospital (MGH) and Washington University School of Medicine report that infusion of an antisense oligonucleotide against SOD1, the first gene to be associated with familial ALS, had no serious adverse effects and the drug was successfully distributed thoughout the central nervous system.

"This therapy directly targets the cause of this form of ALS a mutation in SOD1, which was originally discovered here at the MGH by my mentor Robert Brown," says Merit Cudkowicz, MD, chief of Neurology at MGH and senior author of the report in Lancet Neurology, which has been released online. "It's very exciting that we have reached a stage when we can start clinical trials against this type of ALS."

ALS causes the death of motor neurons in the brain and spinal cord, stopping transmission of neural signals to nerve fibers and leading to weakness, paralysis and usually death from respiratory failure. Only 10 percent of ALS cases are inherited, and mutations in SOD1 which produce an aberrant, toxic form of the protein account for about 20 percent of familial cases. Although that first SOD1 mutation was identified 20 years ago by the team lead by Brown who is now professor and chief of Neurology at the University of Massachusetts Medical School a technology that directly addresses such mutations became available only recently.

The current study, the first author of which is Timothy Miller, MD, PhD, of Washington University, used what are called antisense oligonucleotides small, single-stranded DNA or RNA molecules that prevent production of a protein by binding to its messenger RNA. While antisense medications hav
'/>"/>

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... Abilene, Texas (PRWEB) , ... August 28, 2015 , ... ... penned a new publication and pleads for swift actions to be taken in ... of unnatural disasters. , Yisrayl says scientists have yet to understand fully the ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... PICK: Connexins: providing protection to cells destroyed in type ... lifelong disease characterized by high levels of sugar (glucose) ... immune system attacking and destroying the cells in their ... glucose levels. Surprisingly, little is known about the mechanisms ...
... Goodwin HealthDay Reporter , SUNDAY, Nov. 6 ... fresheners may evoke the holiday season for some. For ... runny, itchy noses and sneezing to asthma attacks. ... risen, so have complaints from their patients about reactions ...
... for the first time, they show significant decreases in crime, ... Researchers assessed more than 200 at-risk boys annually from ... crime, tobacco, alcohol, and marijuana use changed over time. While ... behavior, they had not isolated the additional effects of fatherhood. ...
... cells know what cell types to become? Why do cells ... develop into cancer cells? These are some of the questions ... research has a very strong position internationally and one of ... of Copenhagen. She has just received an ERC Starting Grant ...
... School of Medicine is honored to announce gifts to ... Research Foundation Professorship in Integrative Oncology. This professorship will ... as national leaders in teaching, research, and patient care ... gifts from The Parker Foundation and Helen Moss Cancer ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2Health News:Research in cellular memory 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 3Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: